INS and thyroid gland carcinoma: Here we conducted a nationwide multicenter retrospective cohort study in patients with T2D who were prescribed GLP-1RAs vs insulins or metformin to determine whether GLP-1RAs were associated with changes in the risk of each of 13 OACs, including esophageal, breast, colorectal, endometrial, gallbladder, stomach, kidney, ovarian, pancreatic, and thyroid cancer as well as hepatocellular carcinoma, meningioma, and multiple myeloma.1